These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

284 related articles for article (PubMed ID: 28508457)

  • 1. Effects of canagliflozin on cardiovascular risk factors in patients with type 2 diabetes mellitus.
    Budoff MJ; Wilding JPH
    Int J Clin Pract; 2017 May; 71(5):. PubMed ID: 28508457
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The CANVAS Program: implications of canagliflozin on reducing cardiovascular risk in patients with type 2 diabetes mellitus.
    Carbone S; Dixon DL
    Cardiovasc Diabetol; 2019 May; 18(1):64. PubMed ID: 31138195
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, on blood pressure and markers of arterial stiffness in patients with type 2 diabetes mellitus: a post hoc analysis.
    Pfeifer M; Townsend RR; Davies MJ; Vijapurkar U; Ren J
    Cardiovasc Diabetol; 2017 Feb; 16(1):29. PubMed ID: 28241822
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of canagliflozin in patients with type 2 diabetes based on history of cardiovascular disease or cardiovascular risk factors: a post hoc analysis of pooled data.
    Davies MJ; Merton K; Vijapurkar U; Yee J; Qiu R
    Cardiovasc Diabetol; 2017 Mar; 16(1):40. PubMed ID: 28327140
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fixed-Dose Combination of Canagliflozin and Metformin for the Treatment of Type 2 Diabetes: An Overview.
    Davidson JA; Sloan L
    Adv Ther; 2017 Jan; 34(1):41-59. PubMed ID: 27854055
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical potential of canagliflozin in cardiovascular risk reduction in patients with type 2 diabetes.
    Skelley JW; Carter BS; Roberts MZ
    Vasc Health Risk Manag; 2018; 14():419-428. PubMed ID: 30573964
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rationale, design and baseline characteristics of the CANagliflozin cardioVascular Assessment Study-Renal (CANVAS-R): A randomized, placebo-controlled trial.
    Neal B; Perkovic V; Matthews DR; Mahaffey KW; Fulcher G; Meininger G; Erondu N; Desai M; Shaw W; Vercruysse F; Yee J; Deng H; de Zeeuw D;
    Diabetes Obes Metab; 2017 Mar; 19(3):387-393. PubMed ID: 28120497
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The potential role of sodium glucose co-transporter 2 inhibitors in the early treatment of type 2 diabetes mellitus.
    Brunton SA
    Int J Clin Pract; 2015 Oct; 69(10):1071-87. PubMed ID: 26147213
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Canagliflozin: a sodium glucose co-transporter 2 inhibitor for the treatment of type 2 diabetes mellitus.
    Rosenthal N; Meininger G; Ways K; Polidori D; Desai M; Qiu R; Alba M; Vercruysse F; Balis D; Shaw W; Edwards R; Bull S; Di Prospero N; Sha S; Rothenberg P; Canovatchel W; Demarest K
    Ann N Y Acad Sci; 2015 Nov; 1358():28-43. PubMed ID: 26305874
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Canagliflozin and cardiovascular outcomes in Type 2 diabetes.
    Sarraju A; Spencer-Bonilla G; Rodriguez F; Mahaffey KW
    Future Cardiol; 2021 Jan; 17(1):39-48. PubMed ID: 32748638
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bone effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in patients with type 2 diabetes mellitus.
    Blevins TC; Farooki A
    Postgrad Med; 2017 Jan; 129(1):159-168. PubMed ID: 27894216
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term safety and efficacy of canagliflozin as add-on therapy to teneligliptin in Japanese patients with type 2 diabetes.
    Kadowaki T; Inagaki N; Kondo K; Nishimura K; Kaneko G; Maruyama N; Nakanishi N; Watanabe Y; Gouda M; Iijima H
    Diabetes Obes Metab; 2018 Jan; 20(1):77-84. PubMed ID: 28608617
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of canagliflozin on nocturnal home blood pressure in Japanese patients with type 2 diabetes mellitus: The SHIFT-J study.
    Kario K; Hoshide S; Okawara Y; Tomitani N; Yamauchi K; Ohbayashi H; Itabashi N; Matsumoto Y; Kanegae H
    J Clin Hypertens (Greenwich); 2018 Oct; 20(10):1527-1535. PubMed ID: 30246286
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of Canagliflozin on Cardiovascular Biomarkers in Older Adults With Type 2 Diabetes.
    Januzzi JL; Butler J; Jarolim P; Sattar N; Vijapurkar U; Desai M; Davies MJ
    J Am Coll Cardiol; 2017 Aug; 70(6):704-712. PubMed ID: 28619659
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SGLT2 inhibitors with cardiovascular benefits: Transforming clinical care in Type 2 diabetes mellitus.
    d'Emden M; Amerena J; Deed G; Pollock C; Cooper ME
    Diabetes Res Clin Pract; 2018 Feb; 136():23-31. PubMed ID: 29196150
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SGLT-2 inhibitors in diabetes: a focus on renoprotection.
    Gonzalez DE; Foresto RD; Ribeiro AB
    Rev Assoc Med Bras (1992); 2020 Jan; 66Suppl 1(Suppl 1):s17-s24. PubMed ID: 31939531
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of Canagliflozin on Renal and Cardiovascular Outcomes across Different Levels of Albuminuria: Data from the CANVAS Program.
    Neuen BL; Ohkuma T; Neal B; Matthews DR; de Zeeuw D; Mahaffey KW; Fulcher G; Li Q; Jardine M; Oh R; Heerspink HL; Perkovic V
    J Am Soc Nephrol; 2019 Nov; 30(11):2229-2242. PubMed ID: 31530577
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cardiovascular Effects of New Oral Glucose-Lowering Agents: DPP-4 and SGLT-2 Inhibitors.
    Scheen AJ
    Circ Res; 2018 May; 122(10):1439-1459. PubMed ID: 29748368
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sodium-glucose cotransporter type 2 inhibitors for the treatment of type 2 diabetes mellitus.
    Scheen AJ
    Nat Rev Endocrinol; 2020 Oct; 16(10):556-577. PubMed ID: 32855502
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Economic modelling of costs associated with outcomes reported for type 2 diabetes mellitus (T2DM) patients in the CANVAS and EMPA-REG cardiovascular outcomes trials.
    Kamstra R; Durkin M; Cai J; Bookhart B; Lafeuille MH; Pilon D; Tiggelaar S; Manceur AM; Lefebvre P
    J Med Econ; 2019 Mar; 22(3):280-287. PubMed ID: 30575426
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.